Al-Daw'a increases Aneyah stake to 63%
The Saudi Pharmaceutical Industries Company (SPIMACO) has increased its stake in ‘Inaya’ from 51% to 63% through the acquisition of a 12% share valued at 45 million Saudi Riyals from AXENDRA Health. This move strengthens its investments in the medical sector and aims to support integration with local companies operating in the field. The company expects the financial impact of the deal to begin reflecting from the second half of 2026. Inaya achieved revenues of 237 million Riyals in 2025, with profits rising to 45.36 million Riyals.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)